Spotlight on prostate cancer: the latest evidence and current controversies

BMC Medicine

Andrew Vickers¹  Sigrid Carlsson² 

[1] Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, New York 10017, NY, USA;Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Göteborg, Göteborg, Sweden

关键词: Risk stratification;    Treatment;    Screening;    Prevention;    Prostate cancer;   

Others  :  1140487
DOI  :  10.1186/s12916-015-0311-x

 received in 2015-03-04, accepted in 2015-03-04,  发布年份 2015

【 摘 要 】

Recent decades have seen dramatic changes in the management of prostate cancer based on novel research findings. Prostate-specific antigen (PSA) screening has been introduced, and then recently modified to include new strategies and biomarkers. Management of advanced disease has been transformed by the rapid introduction of new agents. We have moved from a “one-size-fits-all” approach in prostate cancer management to multidisciplinary strategies tailored to the individual patient and his specific cancer. This editorial marks the launch of the article collection Spotlight on prostate cancer (http://www.biomedcentral.com/bmcmed/series/SPR), and here, guest editors Sigrid Carlsson and Andrew Vickers give an overview of the past, present, and future of prostate cancer research and management.

【 授权许可】

   
2015 Carlsson and Vickers; licensee BioMed Central.

【 参考文献 】

• [1]Adams J: The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet 1853, 1:393.
• [2]Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015, 65:5-29.
• [3]Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al.: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-403.
• [4]Lin PH, Aronson W, Freedland SJ: Nutrition, dietary interventions and prostate cancer: the latest evidence. BMC Medicine 2015, 13:3. http://www.biomedcentral.com/1741-7015/13/3 BioMed Central Full Text
• [5]Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al.: Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008, 19:175-81.
• [6]Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al.: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014, 384:2027-35.
• [7]Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al.: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010, 11:725-32.
• [8]Loeb S: Guideline of guidelines: prostate cancer screening. BJU Int 2014, 114:323-5.
• [9]Moyer VA: U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157:120-34.
• [10]Kim EH, Andriole GL. Prostate-specific antigen based screening: controversy and guidelines. BMC Medicine. 2015. DOI: 10.1186/s12916-015-0296-5.
• [11]Andriole GL, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al.: Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104:1-8.
• [12]Bill-Axelson A, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al.: Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014, 370:932-42.
• [13]Wilt TJ, et al.: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-13.